I
107TH CONGRESS
1ST SESSION
H. R. 2172
To amend the Federal Food, Drug, and Cosmetic Act with respect to the
cloning of humans, and for other purposes.
IN THE HOUSE OF REPRESENTATIVES
JUNE 14, 2001
Mr. GREENWOOD (for himself, Mr. WOLF, Mr. OWENS, Mr. NEAL of Massa-
chusetts, Mr. PALLONE, Mrs. MCCARTHY of New York, Mr. DEUTSCH,
Mr. GILLMOR, and Ms. DEGETTE) introduced the following bill; which
was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act with
respect to the cloning of humans, and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Cloning Prohibition
Act of 2001’’.
SEC. 2. PROHIBITION AGAINST HUMAN CLONING.
(a) IN GENERAL.—The Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 301 et seq.) is amended by add-
ing at the end the following:
‘‘CHAPTER X—HUMAN CLONING
‘‘PROHIBITION AGAINST HUMAN CLONING
‘‘SEC. 1001. (a) NUCLEAR
TRANSFER
TECH-
NOLOGY.—
‘‘(1) IN GENERAL.—It shall be unlawful for any
person—
‘‘(A) to use or attempt to use human so-
matic cell nuclear transfer technology with the
intent to initiate a pregnancy; or
‘‘(B) to ship or transport the cellular prod-
uct resulting from human somatic cell nuclear
transfer technology knowing that the product is
intended to be used to initiate a pregnancy.
‘‘(2) DEFINITION.—For purposes of this sec-
tion, the term ‘human somatic cell nuclear transfer
technology’ means transferring the nucleus of a
human somatic cell into an egg cell from which the
nucleus has been removed or rendered inert.
‘‘(b) RULE OF CONSTRUCTION.—This section may
not be construed as applying to any of the following:
‘‘(1) The use of somatic cell nuclear transfer
technology to clone molecules, DNA, cells, or tissues.
‘‘(2) The use of mitochondrial, cytoplasmic, or
gene therapy.
‘‘(2) with respect to humans, prohibits or re-
stricts research regarding or practices constituting—
‘‘(A) somatic cell nuclear transfer;
‘‘(B) mitochondrial or cytoplasmic therapy;
or
‘‘(C) the cloning of molecules, DNA, cells,
tissues, or organs;
except that this subsection does not apply to any State
or local law that was in effect as of the day before the
date of the enactment of the Cloning Prohibition Act of
2001.
‘‘(e) SUNSET.—This section and section 301(bb) do
not apply to any activity described in subsection (a) that
occurs on or after the expiration of the 10-year period be-
ginning on the date of the enactment of the Cloning Prohi-
bition Act of 2001.
‘‘(f) RIGHT OF ACTION.—This section may not be
construed as establishing any private right of action.’’.
(b) PROHIBITED ACTS.—
(1) IN GENERAL.—Section 301 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is
amended by adding at the end the following:
‘‘(bb) The violation of section 1001(a), or the failure
to register in accordance with section 1001(c).’’.
(2) CRIMINAL PENALTY.—Section 303(b) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C.
333(b)) is amended by adding at the end the fol-
lowing:
‘‘(7) Notwithstanding subsection (a), any person who
violates section 301(bb) shall be imprisoned not more than
10 years or fined in accordance with title 18, United
States Code, or both.’’.
(3) CIVIL PENALTY.—Section 303 of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 333)
is amended by adding at the end the following:
‘‘(h)(1) Any person who violates section 301(bb) shall
be liable to the United States for a civil penalty in an
amount not to exceed the greater of—
‘‘(A) $1,000,000; or
‘‘(B) an amount equal to the amount of any
gross pecuniary gain derived from such violation
multiplied by 2.
‘‘(2) Paragraphs (3) through (5) of subsection (g)
apply with respect to a civil penalty under paragraph (1)
of this subsection to the same extent and in the same man-
ner as such paragraphs (3) through (5) apply with respect
to a civil penalty under paragraph (1) or (2) of subsection
(g).’’.
(4) FORFEITURE.—Section 303 of the Federal
Food, Drug, and Cosmetic Act, as amended by para-
graph (3), is amended by adding at the end the fol-
lowing:
‘‘(i) Any property, real or personal, derived from or
used to commit a violation of section 301(bb), or any prop-
erty traceable to such property, shall be subject to for-
feiture to the United States.’’.
SEC. 3. STUDY BY INSTITUTE OF MEDICINE.
(a) IN GENERAL.—The Secretary of Health and
Human Services (referred to in this section as the ‘‘Sec-
retary’’) shall request the Institute of Medicine to enter
into an agreement with the Secretary under which such
Institute conducts a study to—
(1) review the current state of knowledge about
the biological properties of stem cells obtained from
embryos, fetal tissues, and adult tissues;
(2) evaluate the current state of knowledge
about biological differences among stem cells ob-
tained from embryos, fetal tissues, and adult tissues
and the consequences for research and medicine; and
(3) assess what is currently known about the
ability of stem cells to generate neurons, heart, kid-
ney, blood, liver and other tissues and the potential
clinical uses of these tissues.
(b) OTHER ENTITIES.—If the Institute of Medicine
declines to conduct the study described in subsection (a),
the Secretary shall enter into an agreement with another
appropriate public or nonprofit private entity to conduct
the study.
(c) REPORT.—The Secretary shall ensure that, not
later than three years after the date of the enactment of
this Act, the study required in subsection (a) is completed
and a report describing the findings made in the study
is submitted to the Committee on Energy and Commerce
in the House of Representatives and the Committee on
Health, Education, Labor, and Pensions in the Senate.
Æ